Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocular Safety of Fluticasone Furoate Nasal Spray in Perennial Allergic Rhinitis (2-year, randomized, double-blind, placebo-controlled)
2015-004891-31Phase 4
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in perennial rhinitis comparing Fluticasone furoate nasal spray 110 mcg once daily with Placebo nasal spray once daily (2 arms). Primary endpoint: Time to first occurrence of LOCS III posterior subcapsular opacity (P).
02
Drugs
fluticasone
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on 2015-004891-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004891-31.